Last updated August 25, 2026
Key finding
HOMA Disposition Index improved significantly (p= 0.0075).
The study evaluated the effects of Intestinimonas butyriciproducens on insulin sensitivity and triglycerides in prediabetic participants, finding significant improvements in several metabolic markers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of Intestinimonas butyriciproducens on insulin sensitivity and triglycerides in prediabetic participants, finding significant improvements in several metabolic markers.
These findings are significant as they suggest that Intestinimonas butyriciproducens could be a beneficial intervention for individuals with prediabetes, potentially reducing their risk of developing type 2 diabetes. Improved insulin sensitivity and lower triglyceride levels are crucial for metabolic health, and this treatment may offer a new therapeutic option.
Unclear effectiveness for some outcomes. Limited sample size may affect generalizability. No long-term follow-up data provided.
Published in
Publication details and source links for this paper.
Valentina A, Marina C, Edoardo LMM, et al. Intestinimonas butyriciproducens improves insulin sensitivity and triglycerides in prediabetes. Journal of the Endocrine Society. 2024;8(Suppl 1):bvae163.821. doi:10.1210/jendso/bvae163.821
HOMA Disposition Index improved significantly (p=0.0075).
Triglycerides decreased significantly (phase 1: p=0.0212; phase 2: p=0.0261).
52.6% of participants achieved remission in IFG or IGT after 26 weeks.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Intestinimonas butyriciproducens probiotic supplementation and Advanced glycation end products (AGEs), Disposition Index, Interleukin-10 (IL-10), and 2 more.
This study contributes evidence to
Primary intervention
Intestinimonas butyriciproducens probiotic supplementation
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
5
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Intestinimonas butyriciproducens probiotic supplementation → Advanced glycation end products (AGEs)
Intestinimonas butyriciproducens probiotic supplementation → Advanced glycation end products (AGEs)
Intestinimonas butyriciproducens probiotic supplementation → Disposition Index
Intestinimonas butyriciproducens probiotic supplementation → Disposition Index
Intestinimonas butyriciproducens probiotic supplementation → Interleukin-10 (IL-10)
Intestinimonas butyriciproducens probiotic supplementation → Interleukin-10 (IL-10)
Intestinimonas butyriciproducens probiotic supplementation → Remission of impaired fasting glucose or impaired glucose tolerance
Intestinimonas butyriciproducens probiotic supplementation → Remission of impaired fasting glucose or impaired glucose tolerance
Intestinimonas butyriciproducens probiotic supplementation → Triglycerides
Intestinimonas butyriciproducens probiotic supplementation → Triglycerides
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
Generated from the study's connected evidence using Evidence Intelligence™.
Intestinimonas butyriciproducens probiotic supplementation appears to improve disposition index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Disposition Index
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Intestinimonas butyriciproducens probiotic supplementation appears to improve remission of impaired fasting glucose or impaired glucose tolerance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Remission of impaired fasting glucose or impaired glucose tolerance
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Intestinimonas butyriciproducens probiotic supplementation appears to improve triglycerides.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Triglycerides
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Intestinimonas butyriciproducens probiotic supplementation for advanced glycation end products (AGES).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Advanced glycation end products (AGEs)
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
